|
 |
 |
 |
 |
 |
 |
- Home
- Join or Change Subscription
- GSI Community
- For New Patients
- About GIST
- Pediatric GIST & Carney Triad
- Treatments
- Ask the Professional
- Learning Center
- Voices of GIST
- Educational Materials
- GIST Support Wiki
- Donate
Deforolimus (AP23573)
 | |
 | |
Deforolimus (AP23573)
Deforolimus (AP23573) is an inhibitor of mTOR being developed by Ariad. Phase I-II trials have been completed.
A Phase III trial, called the SUCCEED trial, is now open for patients with metastatic sarcoma.
For information at the site of the manufacturer click here.
